Abbvie Inc. vs Cytokinetics Inc.
ABBV vs CYTK — side-by-side comparison from reported financials. ABBV leads 7, CYTK leads 1 of 8 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Cytokinetics Inc.
CYTK · Healthcare
$62.91+1.45%Strained
| Metric | ABBV | CYTK |
|---|---|---|
| Price | $276.43 | $62.91 |
| Market cap | $488B | $8.75B |
| Revenue (TTM) | $64.4B | $67.7M |
| Revenue growth | +1.8% | -2.4% |
| Net margin | 9.8% | -1321.3% |
| Free cash flow | $18.2B | -$581M |
| Net cash (debt) | ($56.2B) | $636M |
| 1-year price return | +19.8% | +4.3% |
| P/E | 77.4 | — |
| P/E vs own history (cheap-side %) | 23% | — |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -131% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 3 of 11 |
| Employees | 57,000 | 673 |
Full résumé-style profiles: ABBV CV · CYTK CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.